




PHARMACEUTICAL 2019

Skye Bioscience Inc.
Rank 354 of 363





PHARMACEUTICAL 2019

Skye Bioscience Inc.
Rank 354 of 363

The relative strengths and weaknesses of Skye Bioscience Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Skye Bioscience Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 205% points. The greatest weakness of Skye Bioscience Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 282% points.

The company's Economic Capital Ratio, given in the ranking table, is -472%, being 509% points below the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	1,954
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	15,939
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	6,600
Other Liabilities	1,580
Other Net Income	-7,902
Other Revenues	0
Property and Equipment	3.4
Research and Development	330
Selling, General and Administrative Expense	4,363

Output Variable	Value in 1000 USD
Assets	1,957
Liabilities	17,519
Expenses	11,292
Revenues	0
Stockholders Equity	-15,562
Net Income	-19,194
Comprehensive Net Income	-19,194
Economic Capital Ratio	-472%